Chapter 5
Biomanufacturing/GMP Trends
2023 U.S. Life Sciences Outlook
3 Minute Read
Looking for a PDF of this content?
Persistent Demand for New Biomanufacturing/GMP Space
Leasing activity for Biomanufacturing/Good Manufacturing Process (GMP) facilities slowed in 2022 as tenants postponed real estate decisions amid economic uncertainty. Some life sciences companies deferred plans to lease or build their own GMP space due to capital constraints and instead opted to engage third-party drug manufacturers. While demand for space remains significant, there has been a moderate increase in vacancy in most markets as construction ramped up.
The bulk of large-capacity Biomanufacturing/GMP facilities (owner occupied and leased) are in California and the Northeast Corridor (Figure 26).
Figure 26: Top 10 Metros by Biomanufacturing Capacity
Source: BioPLan, CBRE Research, 2022.
Market Indicators
Figure 27 shows select Biomanufacturing/GMP markets for leasable space and their current supply and demand fundamentals. Year-over-year rent growth remains robust in the face of persistent demand.
Figure 27: Select Biomanufacturing/GMP Market Indicators
Source: CBRE Research, 2022.
Note: Rent assumes $100 to $200 in tenant improvement allowance.
Related Service
- Property Type
Life Sciences
We provide the life sciences industry solutions that maximize facility and investment performance across labs, manufacturing space and critical enviro...
Related Insights
- Article | Evolving Workforces
Integrated lab and extended reality solutions: the augmented future of lab asset management with CBRE
February 21, 2023 5 Minute Read
CBRE has pioneered the use of direct collaboration with original equipment manufacturers (OEMs) and on-site troubleshooting, driving forwards faster installatio...
- Chapter | Intelligent Investment
U.S. Real Estate Market Outlook 2023: Life Sciences
December 13, 2022 5 Minute Read
In 2023, Pandemic-fueled demand and capital infusion will give way to more normal market conditions, with better opportunities for occupiers.
- Brief | Intelligent Investment
Lab/R&D Space Market Remains Strong Despite H1 2022 Drop in Life Sciences Funding
August 3, 2022 3 Minute Read
After peaking in 2021, life sciences funding has plunged this year due to market uncertainty.
Contacts
Matthew Gardner
Americas Advisory Leader Life Sciences
Eric Stavriotis
Vice Chairman, Advisory & Transaction Services | Location Incentives
Insights in Your Inbox
Stay up to date on relevant trends and the latest research.